Officer Dennis Mulroy Files to Sell Additional $404K in Stock, Continuing Recent Trend
ANAB has more than doubled off its 52-week low of $11.402.
Summary
AnaptysBio officer Dennis Mulroy has filed a Form 144 indicating intent to sell an additional $404,340 worth of common stock, extending a pattern of significant insider sales totaling over $5.7 million in the past three months.
Key Events · Ownership and Investor Activity · ANAB
-
Officer Files to Sell Stock
Dennis Mulroy, an officer, filed a Form 144 to sell 7,691 shares of common stock, valued at approximately $404,340.
-
Continuation of Selling Trend
This proposed sale extends a pattern of significant insider selling, with Mulroy having already sold 90,731 shares for gross proceeds of over $5.3 million in the past three months.
-
Cumulative Insider Distribution
The total value of shares sold and proposed to be sold by this officer in the last three months exceeds $5.7 million.
-
Context of Recent Corporate Actions
This ongoing insider selling occurs after the company completed its biopharma spin-off and announced a $100 million share repurchase program.
Analysis · ANAB · Life Sciences
This Form 144 filing by officer Dennis Mulroy signals a continued trend of insider selling at AnaptysBio. While the proposed sale of $404,340 is modest on its own, it adds to over $5.3 million in sales by the same officer in the last three months, bringing the total to over $5.7 million. This ongoing distribution by a key executive could be interpreted negatively by investors, especially following the company's recent spin-off and share repurchase program announcement.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANAB was trading at $53.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $11.40 to $72.36. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.